Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors
Abstract
Share and Cite
Vargas-Delgado, A.P.; Arteaga Herrera, E.; Tumbaco Mite, C.; Delgado Cedeno, P.; Van Loon, M.C.; Badimon, J.J. Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors. Int. J. Mol. Sci. 2023, 24, 4144. https://doi.org/10.3390/ijms24044144
Vargas-Delgado AP, Arteaga Herrera E, Tumbaco Mite C, Delgado Cedeno P, Van Loon MC, Badimon JJ. Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors. International Journal of Molecular Sciences. 2023; 24(4):4144. https://doi.org/10.3390/ijms24044144
Chicago/Turabian StyleVargas-Delgado, Ariana P., Estefania Arteaga Herrera, Cesar Tumbaco Mite, Patricia Delgado Cedeno, Maria Cristina Van Loon, and Juan J. Badimon. 2023. "Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors" International Journal of Molecular Sciences 24, no. 4: 4144. https://doi.org/10.3390/ijms24044144
APA StyleVargas-Delgado, A. P., Arteaga Herrera, E., Tumbaco Mite, C., Delgado Cedeno, P., Van Loon, M. C., & Badimon, J. J. (2023). Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors. International Journal of Molecular Sciences, 24(4), 4144. https://doi.org/10.3390/ijms24044144

